Safety and Preliminary Efficacy Study of WST11 (Stakel®)-Mediated VTP Therapy in Subjects With CNV Associated With AMD

Update Il y a 4 ans
Reference: NCT01021956

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The objectives of this study is to evaluate the safety(first objective) and efficacy(second objective)of an experimental drug product,Stakel®, in the treatment of neovascular AMD. The drug product is activated in patients by exposure to light at a specific wavelength ("Vascular Targeted Photodynamic therapy", "VTP"). The exploratory objective is to assess whether it is possible to delay or reduce the requirement for anti VEGF intravitreal therapy in the first 12 weeks after VTP. All subjects will have a 52 weeks safety follow up telephone call.


Inclusion criteria

  • Macular degeneration,Choroidal Neovascularization

Links